Alumis Inc. (ALMS) Reports New Phase 3 Psoriasis Data; NDA Planned for 4Q 2026

Alumis Inc. (ALMS) shared Phase 3 trial data for envudeucitinib, showing 54% of psoriasis patients achieved complete skin clearance at 48 weeks. The drug also demonstrated significant itch reduction and improved quality of life. Alumis plans to file for FDA approval in late 2026.

Alumis Inc. (ALMS) reported positive Phase 3 data for envudeucitinib, showing 54% PASI 100 response at Week 48. The therapy improved scalp clearance, itch relief, and quality of life. Alumis plans to submit an NDA in 4Q 2026. The treatment was well-tolerated with no new safety signals.

H.C. Wainwright reiterated a Buy rating and $15.00 price target on Alumis Inc (ALMS) after positive LATITUDE Atlas trial results for zaso. The stock trades at $6.85, down from its 52-week high. Analysts view the data favorably but note mixed reactions due to recent Phase 2b trial failures for Envudeucitinib.

Alumis (ALMS) stock rose 6.3% in pre-market trading after presenting long-term skin-clearance data for envudeucitinib at the Cantor Fitzgerald Global Healthcare Conference. Management highlighted potential partnerships and insider Srinivas Akkaraju bought 986,000 shares. The FDA application for envudeucitinib is expected in Q4 2026.

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet primary or secondary endpoints in the overall population. However, a prespecified subgroup with high interferon gene signature showed numerically higher responses. The company plans to discuss Phase 3 trial design with regulators. Envudeucitinib was generally well tolerated.

Alumis Inc. (ALMS) shares dropped 57% after its Phase 2b lupus study missed primary goals, though a patient subgroup showed promising results. The company plans to discuss a late-stage trial with regulators. Wells Fargo and Baird lowered price targets but maintained positive ratings. ALMS is down 3% year-to-date.